You are here

  • Home
  • Archive
  • Volume 3, Issue 2
  • Sodium selenate as a disease-modifying treatment for mild–moderate Alzheimer’s disease: an open-label extension study

Article info

Article menu

Download PDFPDF

Original research
Sodium selenate as a disease-modifying treatment for mild–moderate Alzheimer’s disease: an open-label extension study

Authors

  • Lucy Vivash Department of Neuroscience, Monash University, Melbourne, Victoria, AustraliaDepartment of Medicine and Radiology, University of Melbourne, Melbourne, Victoria, AustraliaDepartment of Neurology, Royal Melbourne Hospital, Parkville, Victoria, AustraliaDepartment of Neurology, Alfred Hospital, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Charles B Malpas Department of Neuroscience, Monash University, Melbourne, Victoria, AustraliaDepartment of Neurology, Royal Melbourne Hospital, Parkville, Victoria, AustraliaDepartment of Neurology, Alfred Hospital, Melbourne, Victoria, AustraliaMelbourne School of Psychological Sciences, University of Melbourne, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Christopher M Hovens Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Amy Brodtmann Department of Neurology, Royal Melbourne Hospital, Parkville, Victoria, AustraliaFlorey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Victoria, AustraliaEastern Cognitive Disorders Clinic, Monash University, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Steven Collins Department of Medicine and Radiology, University of Melbourne, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Stephen Macfarlane The Dementia Centre, HammondCare, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Dennis Velakoulis Neuropsychiatry Unit, Royal Melbourne Hospital, Melbourne, Victoria, AustraliaMelbourne Neuropsychiatry Centre, University of Melbourne, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Terence J O’Brien Department of Neuroscience, Monash University, Melbourne, Victoria, AustraliaDepartment of Medicine and Radiology, University of Melbourne, Melbourne, Victoria, AustraliaDepartment of Neurology, Royal Melbourne Hospital, Parkville, Victoria, AustraliaDepartment of Neurology, Alfred Hospital, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Lucy Vivash; lucy.vivash{at}monash.edu
View Full Text

Citation

Vivash L, Malpas CB, Hovens CM, et al
Sodium selenate as a disease-modifying treatment for mild–moderate Alzheimer’s disease: an open-label extension study
BMJ Neurology Open 2021;3:e000223. doi: 10.1136/bmjno-2021-000223

Publication history

  • Received September 20, 2021
  • Accepted November 22, 2021
  • First published December 16, 2021.
Online issue publication 
December 16, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.